Stock Analiz

Cytokinetics Inc. (CYTK) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Cytokinetics’s revenue went from $106M in fiscal 2016 to $88M in fiscal 2025, a decline of about 2.1% a year.

Net income in fiscal 2025 was -$785M, a net margin of -891.6%; the best year in this period was 2016 with $16M.

Over the twelve months to September 30, 2026, revenue was $113M and net income -$778M.

Free cash flow was -$535M in fiscal 2025 and positive in 1 of the 10 years shown.

The diluted share count rose 182% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $106M162017: $13M172018: $32M182019: $27M192020: $56M202021: $70M212022: $95M222023: $8M232024: $18M242025: $88M25$88M
Net income
2016: $16M162017: -$128M172018: -$106M182019: -$122M192020: -$127M202021: -$215M212022: -$389M222023: -$526M232024: -$590M242025: -$785M25-$785M
Free cash flow
2016: $35M162017: -$105M172018: -$102M182019: -$94M192020: -$2M202021: -$191M212022: -$311M222023: -$416M232024: -$400M242025: -$535M25-$535M
EPS (diluted)
2016: $390.00162017: $-2590.00172018: $-1.95182019: $-2.11192020: $-1.97202021: $-2.80212022: $-4.33222023: $-5.45232024: $-5.26242025: $-6.5425$-6.54

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$113M$88M$18M$8M$95M$70M$56M$27M$32M$13M$106M
Gross profit———————————
Operating income-$708M-$612M-$536M-$496M-$324M-$186M-$94M-$99M-$89M-$113M$19M
Net income-$778M-$785M-$590M-$526M-$389M-$215M-$127M-$122M-$106M-$128M$16M
EPS (diluted)$-6.04$-6.54$-5.26$-5.45$-4.33$-2.80$-1.97$-2.11$-1.95$-2590.00$390.00
R&D$403M$416M$339M$330M$241M$160M$97M$86M$89M$90M$60M
Revenue growth—+376.6%+145.3%−92.0%+34.3%+26.2%+107.8%−14.7%+135.6%−87.4%+271.3%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow-$572M-$510M-$396M-$414M-$300M-$143M$9M-$91M-$101M-$102M$37M
Capital spending-$17M-$25M-$4M-$1M-$11M-$49M-$11M-$3M-$889000-$3M-$2M
Free cash flow-$589M-$535M-$400M-$416M-$311M-$191M-$2M-$94M-$102M-$105M$35M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks———————————
Stock-based pay$131M$112M$98M$72M$48M$27M$18M$11M$10M$9M$7M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$882M$1.1B$615M$783M$472M$464M$225M$199M$269M$156M
Debt—$1.1B$751M$778M$789M$174M$49M$52M$53M$32M$30M
Equity—-$660M-$135M-$386M-$108M$244M$113M-$11M$26M$110M$94M
Total assets—$1.4B$1.4B$824M$1.0B$841M$534M$290M$211M$295M$170M
Shares (diluted)129M0M0M0M0M0M0M0M0M0M0M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin———————————
Operating margin-625.2%-695.4%-2902.7%-6589.7%-342.8%-264.5%-168.3%-368.0%-282.3%-848.3%17.6%
Net margin-686.6%-891.6%-3191.1%-6988.6%-411.2%-305.7%-228.0%-452.9%-337.4%-955.9%15.5%
FCF margin-519.5%-607.5%-2164.1%-5521.2%-328.6%-271.8%-3.8%-348.1%-324.1%-782.7%33.3%
ROIC—-103.7%-68.8%-100.2%-37.6%-35.2%-45.6%-190.8%-112.5%-80.1%15.0%
ROE—119.0%435.5%136.2%360.5%-88.3%-112.3%1112.7%-409.8%-116.3%17.4%

Frequently asked questions

What is Cytokinetics’s annual revenue?

$88M in fiscal 2025 and $113M over the twelve months to September 30, 2026.

How much profit does Cytokinetics make?

Net income was -$785M in fiscal 2025 (net margin -891.6%).

Is Cytokinetics’s revenue growing?

Yes: revenue rose 376.6% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.